Amphastar Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

AMPH$29.38+3.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(in thousands, except per share data)


	Year Ended December 31,
· 2025 · · 2024 · · 2023
Net revenues:
Product revenues, net		$719,887	$712,814	$593,238
Other revenues		—	19,153	51,157
Total net revenues		719,887	731,967	644,395

Cost of revenues		363,830	358,112	293,274
Gross profit		356,057	373,855	351,121

Operating expenses:
Selling, distribution, and marketing		43,885	37,802	28,853
General and administrative		85,925	56,720	51,540
Research and development		85,844	73,914	73,741
Total operating expenses		215,654	168,436	154,134

Income from operations		140,403	205,419	196,987

Non-operating expenses:
Interest income		8,679	10,612	5,459
Interest expense		(25,481)	(30,343)	(27,158)
Other income (expenses), net		23	4,076	(3,929)
Total non-operating expenses, net		(16,779)	(15,655)	(25,628)

Income before income taxes		123,624	189,764	171,359
Income tax provision		25,530	29,672	31,833
Income before equity in losses of unconsolidated affiliate		98,094	160,092	139,526

Equity in losses of unconsolidated affiliate		—	(573)	(1,981)

Net income		$98,094	$159,519	$137,545

Net income per share:
Basic		$2.10	$3.29	$2.85

Diluted		$2.03	$3.06	$2.60

Weighted-average shares used to compute net income per share:
Basic		46,743	48,429	48,265

Diluted		48,215	52,058	53,001

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.